Leerink Partnrs Has Negative Outlook of DNLI FY2028 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Leerink Partnrs lowered their FY2028 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $0.50 for the year, down from their previous forecast of $0.55. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ FY2029 earnings at $0.80 EPS.

Several other equities analysts also recently weighed in on DNLI. JPMorgan Chase & Co. raised their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley reduced their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics currently has a consensus rating of “Buy” and an average price target of $32.64.

Denali Therapeutics Trading Up 12.7%

NASDAQ:DNLI opened at $17.58 on Tuesday. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $31.47. The company has a quick ratio of 9.79, a current ratio of 9.79 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $15.13 and a 200-day simple moving average of $14.70. The company has a market capitalization of $2.58 billion, a PE ratio of -6.04 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same period in the previous year, the company earned ($0.63) EPS. Denali Therapeutics’s revenue was up .0% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNLI. Vanguard Group Inc. boosted its holdings in shares of Denali Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 11,992,918 shares of the company’s stock worth $174,137,000 after purchasing an additional 182,183 shares during the last quarter. Wellington Management Group LLP lifted its position in Denali Therapeutics by 15.9% during the first quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company’s stock worth $155,113,000 after buying an additional 1,561,647 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Denali Therapeutics by 88.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock worth $91,996,000 after buying an additional 3,184,042 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Denali Therapeutics by 42.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company’s stock worth $59,373,000 after buying an additional 1,308,619 shares during the last quarter. Finally, Norges Bank purchased a new stake in Denali Therapeutics in the 2nd quarter valued at about $55,224,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.